Hepatocellular Carcinoma, Hepatitis B
Conditions
Brief summary
Chronic hepatitis B (CHB) can lead to hepatocellular carcinoma (HCC), imposing a significant health and economic burden globally. Early detection of hepatitis B virus-related HCC (HBV-HCC) in CHB with potential biomarkers has become a pressing and difficult challenge. Recent advancements in urinary proteomics offer a promising approach for HBV-HCC biomarker identification, utilizing Liquid chromatography with tandem mass spectrometry for urine proteome analysis. Differential analysis using limma in R software will uncover upregulated proteins in HBV-HCC.
Interventions
DIAGNOSTIC_TESTUrine test
Urine samples were collected and their proteomes were analyzed via liquid chromatography with tandem mass spectrometry using data-dependent acquisition or parallel reaction monitoring.
Sponsors
Peking Union Medical College Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
Yes
Inclusion criteria
1. Age \> 18 years old; 2. Previously healthy individuals without underlying diseases, confirmed to be free of hepatitis B infection through HBV serum markers, with regular physical examinations and blood biochemistry tests; 3. Chronic hepatitis B patients diagnosed through HBV serum markers, alpha-fetoprotein (AFP) concentration, clinical features, or imaging examinations; 4. Hepatitis B-related liver cancer patients with complete clinical data, preoperatively tested positive for HBsAg, diagnosed based on clinical features and imaging examinations preoperatively, and pathologically confirmed with HCC postoperatively; 5. Patients with non-hepatocellular liver cancer, preoperatively diagnosed based on clinical features and imaging examinations, with negative HBsAg, and pathologically or by biopsy confirmed as non-hepatocellular liver cancer without liver metastasis, with complete clinical data and no liver metastasis; 6. Able to independently sign an informed consent form.
Exclusion criteria
1. Patients with long-term heavy alcohol consumption; 2. Patients with chronic hepatitis C infection; 3. Patients with autoimmune diseases; 4. Patients who have taken drugs known to have definite hepatotoxicity within the past year; 5. Patients with urinary system infections; 6. Patients with hematuria; 7. Patients with significant proteinuria; 8. Patients with tumors of the urinary system; 9. Patients with acute infectious diseases; 10. Patients with hepatitis B-related liver cancer who also have tumors other than primary hepatocellular carcinoma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| upregulated proteins | 2024-5 |
| downregulated proteins | 2024-5 |
Countries
China
Outcome results
None listed